Last reviewed · How we verify
Hantavax injection
Hantavax is an inactivated vaccine that stimulates the immune system to produce antibodies against hantavirus, preventing infection with hantaviruses that cause hemorrhagic fever with renal syndrome (HFRS).
Hantavax is an inactivated vaccine that stimulates the immune system to produce antibodies against hantavirus, preventing infection with hantaviruses that cause hemorrhagic fever with renal syndrome (HFRS). Used for Prevention of hemorrhagic fever with renal syndrome (HFRS) caused by hantavirus infection.
At a glance
| Generic name | Hantavax injection |
|---|---|
| Sponsor | Green Cross Corporation |
| Drug class | Inactivated viral vaccine |
| Modality | Small molecule |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains inactivated hantavirus antigens that trigger both humoral and cellular immune responses. Upon exposure to wild-type hantavirus, the pre-existing antibodies and memory immune cells provide protection against infection and disease progression. This is a prophylactic immunization approach rather than a direct molecular targeting mechanism.
Approved indications
- Prevention of hemorrhagic fever with renal syndrome (HFRS) caused by hantavirus infection
Common side effects
- Injection site pain or erythema
- Fever
- Myalgia
- Headache
Key clinical trials
- Study to Evaluate the Immunogenicity and Safety of Hantavax in Healthy Adult (PHASE3)
- Study to Evalutate Long-term Immunity of Hantavax in High Risk Population of HFRS (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |